Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis

References

• Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N. 2020. Naturally occurring PCSK9 inhibitors. Nutrients. 12(5):1440. doi:10.3390/nu12051440.
   PubMed Web of Science ®Google Scholar
• Affuso F, Mercurio V, Ruvolo A, Pirozzi C, Micillo F, Carlomagno G, Grieco F, Fazio S. 2012. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 4(3):77–83. doi:10.4330/wjc.v4.i3.77.
   PubMedGoogle Scholar
• Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. 2010. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis. 20(9):656–661. doi:10.1016/j.numecd.2009.05.017.
   PubMed Web of Science ®Google Scholar
• Afsharinasab M, Mohammad-Sadeghipour M, Reza Hajizadeh M, Khoshdel A, Mirzaiey V, Mahmoodi M. 2020. The effect of hydroalcoholic Berberis integerrima fruits extract on the lipid profile, antioxidant parameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease. Saudi J Biol Sci. 27(8):2031–2037. doi:10.1016/j.sjbs.2020.04.037.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. 2015. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 372(25):2387–2397. doi:10.1056/NEJMoa1410489.
   PubMed Web of Science ®Google Scholar
• Chan M, Qin Z, Man S-C, Lam M, Lai WH, Ng RMK, Lee CK, Wong TL, Lee EHM, Wong HK, et al. 2022. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial [published correction appears in Psychiatry Clin Neurosci. 2022 Oct;76(10):536]. Psychiatry Clin Neurosci. 76(3):77–85. doi:10.1111/pcn.13323.
   PubMed Web of Science ®Google Scholar
• Cianci A, Cicero AF, Colacurci N, Matarazzo MG, De Leo V. 2012. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecol Endocrinol. 28(9):699–702. doi:10.3109/09513590.2011.652250.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Bove M, Giovannini M, Veronesi M, Borghi C. 2019. Short-term effects of dry extracts of artichokeand berberis in hypercholesterolemic patients without cardiovascular disease. Am J Cardiol. 123(4):588–591. doi:10.1016/j.amjcard.2018.11.018.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Bove M, Ventura F, Giovannini M, Borghi C. 2018. Optimizing lipid pattern by adding a combined nutraceutical or pravastatin to fenofibrate treatment in hypertriglyceridemic subjects: single site, randomized, open-label, post-market clinical investigation. High Blood Press Cardiovasc Prev. 25(4):355–359. doi:10.1007/s40292-018-0277-9.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Morbini M, Colletti A, Bove M, Veronesi M, Giovannini M, Borghi C. 2017. Nutraceutical effects on glucose and lipid metabolism in patients with impaired fasting glucose: a pilot, double-blind, placebo-controlled, randomized clinical trial on a combined product. High Blood Press Cardiovasc Prev. 24(3):283–288. doi:10.1007/s40292-017-0206-3.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, Toth PP, Rizzo M. 2021. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels? Curr Atheroscler Rep. 23(10):57. doi:10.1007/s11883-021-00955-y.
   PubMed Web of Science ®Google Scholar
• D’Addato S, Scandiani L, Mombelli G, Focanti F, Pelacchi F, Salvatori E, Di Loreto G, Comandini A, Maffioli P, Derosa G, et al. 2017. Effect of a food supplement containing berberine, ­monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study. Drug Des Devel Ther. 11:1585–1592. Published 2017 May 23. doi:10.2147/DDDT.S128623.
   PubMed Web of Science ®Google Scholar
• Dahlberg CJ, Ou JJ, Babish JG, Lamb JJ, Eliason S, Brabazon H, Gao W, Kaadige MR, Tripp ML. 2017. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Can J Physiol Pharmacol. 95(12):1414–1425. doi:10.1139/cjpp-2016-0704.
   PubMed Web of Science ®Google Scholar
• Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, et al. 2021. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 6(2):139–147. doi:10.1001/jamacardio.2020.3151.
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, Romano D, D’Angelo A, Fogari E, Maffioli P. 2013a. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents. 27(3):717–728.
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, Romano D, D’Angelo A, Fogari E, Maffioli P. 2013b. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther. 13(11):1495–1506. doi:10.1517/14712598.2013.832751.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. 2013c. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther. 13(4):475–482. doi:10.1517/14712598.2013.776037.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Maffioli P. 2016. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clin Nutr. 35(5):1091–1095. doi:10.1016/j.clnu.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Romano D, Maffioli P. 2017. Effects of a combination of Berberis aristata, Silybum marianum and monacolin on lipid profile in subjects at low cardiovascular risk; a double-blind, randomized, placebo-controlled trial. Int J Mol Sci. 18(2):343. Published 2017 Feb 7. doi:10.3390/ijms18020343.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Vanelli A, Maffioli P. 2020. An evaluation of a nutraceutical with berberine, curcumin, inositol, banaba and chromium picolinate in patients with fasting dysglycemia. Diabetes Metab Syndr Obes. 13:653–661. Published 2020 Mar 3. doi:10.2147/DMSO.S232791.
   PubMed Web of Science ®Google Scholar
• Derosa G, Romano D, D’Angelo A, Maffioli P. 2015a. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis. 239(1):87–92. doi:10.1016/j.atherosclerosis.2014.12.043.
   PubMed Web of Science ®Google Scholar
• Derosa G, Romano D, D’Angelo A, Maffioli P. 2015b. Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine. 22(2):231–237. doi:10.1016/j.phymed.2014.11.018.
   PubMed Web of Science ®Google Scholar
• Dong B, Li H, Singh AB, Cao A, Liu J. 2015. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 290(7):4047–4058. doi:10.1074/jbc.M114.597229.
   PubMed Web of Science ®Google Scholar
• Emamat H, Zahedmehr A, Asadian S, Nasrollahzadeh J. 2022. The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial. BMC Complement Med Ther. 22(1):59. Published 2022 Mar 7. doi:10.1186/s12906-022-03539-8.
   PubMedGoogle Scholar
• Gentile M, Calcaterra I, Strazzullo A, Pagano C, Pacioni D, Speranza E, Rubba P, Marotta G. 2015. Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. Clin Lipidol. 10(6):475–480. doi:10.2217/clp.15.37.
   PubMed Web of Science ®Google Scholar
• Ghafarzadegan R, Javaheri J, Asgari M, Golitaleb M, Maraki F, Ghafarzadegan R, Zarei M. 2021. The effect of combined herbal capsule on glycemic indices and lipid profile in patients with type 2 diabetes mellitus: a randomized controlled clinical trial. Jundishapur J Nat Pharm Prod. 16(4):e109488. doi:10.5812/jjnpp.109488.
   Web of Science ®Google Scholar
• Gobalakrishnan S, Asirvatham SS, Janarthanam V. 2016. Effect of silybin on lipid profile in hypercholesterolaemic rats. J Clin Diagn Res. 10(4):FF01–FF05. doi:10.7860/JCDR/2016/16393.7566.
   PubMedGoogle Scholar
• Gonnelli S, Caffarelli C, Stolakis K, Cuda C, Giordano N, Nuti R. 2015. Efficacy and tolerability of a nutraceutical combination (red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: A double-blind, placebo-controlled study. Curr Ther Res Clin Exp. 77:1–6. Published 2014 Nov 15. doi:10.1016/j.curtheres.2014.07.003.
   PubMedGoogle Scholar
• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2019. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med. 21(11):1539–1558. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Huang Y-H, Chen S-T, Liu F-H, Hsieh S-H, Lin C-H, Liou M-J, Wang C-C, Huang C-H, Liu G-H, Lin J-R, et al. 2019. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial. PLoS One. 14(8):e0221199. Published 2019 Aug 15. doi:10.1371/journal.pone.0221199.
   PubMed Web of Science ®Google Scholar
• Iloon Kashkooli R, Najafi SS, Sharif F, Hamedi A, Hoseini Asl MK, Najafi Kalyani M, Birjandi M. 2015. The effect of berberis vulgaris extract on transaminase activities in non-alcoholic fatty liver disease. Hepat Mon. 15(2):e25067. Published 2015 Feb 5. doi:10.5812/hepatmon.25067.
   PubMed Web of Science ®Google Scholar
• Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, Trimarco B. 2010. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens. 28(7):1482–1487. doi:10.1097/HJH.0b013e3283395208.
   PubMed Web of Science ®Google Scholar
• Knapp G, Hartung J. 2003. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 22(17):2693–2710. doi:10.1002/sim.1482.
   PubMed Web of Science ®Google Scholar
• Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, Jia Q, Li J. 2021. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 300:113899. doi:10.1016/j.psychres.2021.113899.
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. 2014. A meta-analysis of red yeast rice: An effective and relatively safe alternative approach for dyslipidemia. PLoS One. 9(6):e98611. doi:10.1371/journal.pone.0098611.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G, et al. 2011. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther. 28(12):1105–1113. doi:10.1007/s12325-011-0082-5.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Campolongo G, Pelliccia F, Quattrino S, Vitale C, Cacciotti L, Massaro R, Volterrani M, Rosano G. 2017. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am J Cardiol. 120(6):893–897. doi:10.1016/j.amjcard.2017.06.015.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, Gaudio C, Rosano G. 2015. Usefulness of nutraceuticals (armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol. 116(12):1798–1801. doi:10.1016/j.amjcard.2015.09.023.
   PubMed Web of Science ®Google Scholar
• Mazza A, Nicoletti M, Lenti S, Torin G, Rigatelli G, Pellizzato M, Fratter A. 2021. Effectiveness and safety of novel nutraceutical formulation added to ezetimibe in statin-intolerant hypercholesterolemic subjects with moderate-to-high cardiovascular risk. J Med Food. 24(1):59–66. doi:10.1089/jmf.2020.0019.
   PubMed Web of Science ®Google Scholar
• Mazza A, Schiavon L, Rigatelli G, Torin G, Lenti S. 2019. The effects of a new generation of nutraceutical compounds on lipid profile and glycaemia in subjects with pre-hypertension. High Blood Press Cardiovasc Prev. 26(4):345–350. doi:10.1007/s40292-019-00332-6.
   PubMed Web of Science ®Google Scholar
• Mishra N, Verma R, Jadaun P. 2022. Study on the effect of berberine, myoinositol, and metformin in women with polycystic ovary syndrome: A prospective randomised study. Cureus. 14(1):e21781. Published 2022 Jan 31. doi:10.7759/cureus.21781.
   PubMed Web of Science ®Google Scholar
• Nejati L, Movahedi A, Salari G, Moeineddin R, Nejati P. 2022. The effect of berberine on lipid profile, liver enzymes, and fasting blood glucose in patients with non-alcoholic fatty liver disease (NAFLD): a randomized controlled trial. Med J Islam Repub Iran. 36:39. Published 2022 Apr 20. doi:10.47176/mjiri.36.39.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Pirro M, Lupattelli G, Del Giorno R, Schillaci G, Berisha S, Mannarino MR, Bagaglia F, Melis F, Mannarino E. 2013. Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients. PharmaNutrition. 1(2):73–77. doi:10.1016/j.phanu.2013.02.003.
   Google Scholar
• Pirro M, Mannarino MR, Ministrini S, Fallarino F, Lupattelli G, Bianconi V, Bagaglia F, Mannarino E. 2016. Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci Rep. 6:23587. Published 2016 Mar 23. doi:10.1038/srep23587.
   PubMed Web of Science ®Google Scholar
• Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS, et al. 2022. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 43(48):5047–5057. doi:10.1093/eurheartj/ehac615.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Gomaraschi M, Mombelli G, Macchi C, Bosisio R, Pazzucconi F, Pavanello C, Calabresi L, Arnoldi A, Sirtori CR, et al. 2014. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol. 8(1):61–68. doi:10.1016/j.jacl.2013.11.003.
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma B, Jindal M, Gupta A, Kunwar R, Lata S, Yadav A. 2017. Evaluation of hypolipidemic effect of stem part of Berberis aristata in Type 2 diabetes mellitus patients as add on therapy. Natl J Physiol Pharm Pharmacol. 7(11):1159. doi:10.5455/njppp.2017.7.0517510062017.
   Google Scholar
• Smith KW, White CM. 2022. Inclisiran: a novel small interfering RNA drug for low-density lipoprotein reduction. J Clin Pharmacol. 62(9):1079–1085. doi:10.1002/jcph.2045.
   PubMed Web of Science ®Google Scholar
• Solà R, Valls R-M, Puzo J, Calabuig J-R, Brea A, Pedret A, Moriña D, Villar J, Millán J, Anguera A, et al. 2014. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 9(8):e101978. Published 2014 Aug 1. doi:10.1371/journal.pone.0101978.
   PubMed Web of Science ®Google Scholar
• Spigoni V, Aldigeri R, Antonini M, Micheli M, Fantuzzi F, Fratter A, Pellizzato M, Derlindati E, Zavaroni I, Bonadonna R, et al. 2017. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. IJMS. 18(7):1498. Published 2017 Jul 12. doi:10.3390/ijms18071498.
   Google Scholar
• Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. 2019. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins JPT, Langan D, Salanti G, et al. 2016. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 7(1):55–79. doi:10.1002/jrsm.1164.
   PubMed Web of Science ®Google Scholar
• Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y, et al. 2012. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 166(1):99–105. doi:10.1530/EJE-11-0616.
   PubMed Web of Science ®Google Scholar
• White CM. 2002. HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary. 37:205–221. https://go.gale.com/ps/i.do?id=GALE%7CA95176587.
   Google Scholar
• White CM. 2015. Dec Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab. Ann Pharmacother. 49(12):1327–1335. doi:10.1177/1060028015608487.
   PubMed Web of Science ®Google Scholar
• White CM. 2018. The pharmacologic role and clinical utility of PCSK9 inhibitors for the treatment of hypercholesterolemia. J Cardiovasc Pharmacol Ther. 23(4):301–308. doi:10.1177/1074248418769040.
   PubMed Web of Science ®Google Scholar
• White CM. 2022. Using national guidelines to determine hyperlipidemia treatment. Pharm Pract News; [accessed 2022 Nov 11]. https://www.pharmacypracticenews.com/Clinical/Article/06-22/Using-National-Guidelines-to-Determine-Hyperlipidemia-Treatment/67209.
   Google Scholar
• Zeman M, Vecka M, Perlík F, Hromádka R, Staňková B, Tvrzická E, Žák A. 2015. Niacin in the treatment of hyperlipidemias in light of new clinical trials: has niacin lost its place? Med Sci Monit. 21:2156–2162. doi:10.12659/MSM.893619.
   PubMed Web of Science ®Google Scholar
• Zhao JV, Yeung W-F, Chan Y-H, Vackova D, Leung JYY, Ip DKM, Zhao J, Ho W-K, Tse H-F, Schooling CM, et al. 2021. Effect of berberine on cardiovascular disease risk factors: A mechanistic randomized controlled trial. Nutrients. 13(8):2550. Published 2021 Jul 26. doi:10.3390/nu13082550.
   PubMed Web of Science ®Google Scholar